Otitis externaMANAGEMENT

INFECTIOUS DISEASE PRESENTATIONS · 12 SECTIONS

⚲

475 items

☷ Legend

01Approach to the Critical Patient/attcp48

Immediate priorities and red flags

›Triage and stabilization

›Airway patency

›Respiratory distress

›Hemodynamic instability

›Sepsis physiology

›If toxic appearance or altered mental status, escalate to resuscitation workflow

›High risk features for complicated otitis externa

›Diabetes mellitus

›Immunocompromised state

›Older age with severe otalgia

›Refractory symptoms despite 48 to 72 hours of topical therapy

›Cranial neuropathies

›Severe nocturnal otalgia

›Granulation tissue at bony cartilaginous junction

›Cellulitis beyond ear canal

›Trismus

›Mastoid tenderness or swelling

›If concern for malignant otitis externa, urgent ENT and imaging

›Pain and nausea control

›Rapid analgesia pathway

›Antiemetic support when pain related vomiting

›Hearing and tympanic membrane safety

›If tympanic membrane perforation cannot be excluded, avoid ototoxic drops

›If foreign body suspected, avoid blind instrumentation

Key concepts

›Condition framing

›Acute otitis externa as inflammation or infection of external auditory canal skin

›Predominant pathogens

›Pseudomonas aeruginosa

›Staphylococcus aureus

›Time sensitive inflection points

›Meaningful improvement usually within 48 to 72 hours of appropriate topical therapy

›If worsening after 48 to 72 hours, reassessment for obstruction, wrong diagnosis, or extension

›Evidence and guideline anchors

›Topical therapy as first line for uncomplicated acute otitis externa

›Class I recommendation based on specialty guideline consensus

›ACEP Level C recommendation for ED management workflow

›Systemic antibiotics not routine for uncomplicated disease

›Class I recommendation based on specialty guideline consensus

›ACEP Level C recommendation

Consultation triggers

›ENT escalation

›Suspected malignant otitis externa or skull base osteomyelitis

›Cranial nerve deficits

›Immunocompromised with severe disease

›Canal fully occluded with inability to deliver drops despite wick attempts

›Recurrent disease with suspected anatomic obstruction

›ID or medicine escalation

›Suspected invasive infection

›Need for IV antipseudomonal therapy

02History/hx51

Symptom pattern and exposures

›Presenting features

›Otalgia severity and trajectory

›Otorrhea character

›Pruritus

›Aural fullness

›Conductive hearing loss

›Fever

›Jaw pain or trismus

›Timeline

›Onset date and progression

›Prior similar episodes

›Prior response to topical drops

›Exposure history

›Recent swimming or water exposure

›Humidity or sweating exposure

›Ear canal trauma

›Cotton swab use

›Fingernail scratching

›Earbud or hearing aid irritation

›Recent ear instrumentation

›Syringing or irrigation

›Cerumen removal

›Medication and allergy context

›Current topical ear products

›Antibiotic exposure in last 30 days

›Fluoroquinolone allergy

›Aminoglycoside exposure history

Risk factors and host modifiers

›Host risks

›Diabetes mellitus

›HIV

›Chemotherapy or neutropenia

›Chronic steroid use

›Solid organ transplant

›Dermatologic risks

›Atopic dermatitis

›Psoriasis

›Seborrheic dermatitis

›Anatomic and device risks

›Hearing aids

›Ear molds

›Chronic otorrhea history

›Prior tympanic membrane perforation or ear surgery

Complication screen

›Extension symptoms

›Facial weakness

›Dysphagia

›Hoarseness

›Diplopia

›Headache

›Neck pain

›Periauricular swelling

›Severe persistent night pain

03Physical Exam/exam39

Vitals and general assessment

›Initial assessment

›Temperature

›Heart rate

›Blood pressure

›Respiratory rate

›Oxygen saturation

›Toxic appearance

›Dehydration from poor intake

Ear and head and neck exam

›External ear and canal

›Tragal tenderness

›Pinna manipulation pain

›Canal edema

›Canal erythema

›Debris or purulence

›Fungal elements

›Fluffy white or black spores

›Thick hyphae like debris

›Furuncle or focal abscess

›Cellulitis of pinna or periauricular skin

›Otoscopy and tympanic membrane status

›Visualization adequacy

›Tympanic membrane integrity

›Middle ear effusion signs

›If tympanic membrane not visualized due to edema or debris, perforation status uncertain

›Mastoid and surrounding structures

›Mastoid tenderness

›Postauricular swelling or erythema

›Auricle displacement

›Cranial nerves and complications

›Facial nerve function

›Lower cranial nerve screen

›Trismus assessment

›Cervical lymphadenopathy

PITFALLS

›Common errors

›Mislabeling otitis media with otorrhea as otitis externa

›Missing malignant otitis externa in diabetes

›Inadequate drop delivery due to canal obstruction

›Ototoxic drops when perforation cannot be excluded

›Failure to address underlying dermatitis leading to recurrence

04Differential Diagnosis/ddx20

Otologic and dermatologic mimics

›Primary differential set

›Acute otitis media with tympanic membrane perforation ICD-10 H66

›Chronic suppurative otitis media ICD-10 H66.3

›Otomycosis fungal otitis externa

›Cerumen impaction ICD-10 H61.2

›External auditory canal foreign body ICD-10 T16

›Furunculosis localized canal abscess

›Contact dermatitis or eczema of ear canal

›Psoriasis involving external auditory canal

›Herpes zoster oticus Ramsay Hunt syndrome ICD-10 B02.21

›Perichondritis of pinna ICD-10 H61.0

›Acute mastoiditis ICD-10 H70

›Malignant otitis externa and skull base osteomyelitis ICD-10 H60.2 and M86

Differentiating clues

›Pattern recognition

›Pain with tragal or pinna manipulation favoring otitis externa

›Middle ear effusion or bulging tympanic membrane favoring otitis media

›Vesicles and facial weakness favoring zoster oticus

›Diffuse pinna swelling and sparing of lobule favoring perichondritis

›Postauricular swelling and auricle protrusion favoring mastoiditis

›Severe night pain and granulation tissue in diabetes favoring malignant otitis externa

05Laboratory Tests/lt24

Routine labs and when they matter

›Baseline testing strategy

›No routine labs for uncomplicated acute otitis externa

›Point of care glucose for diabetes concern or severe infection

›HbA1c coordination in recurrent disease with suspected uncontrolled diabetes

Severe disease and extension evaluation

›Invasive infection workup

›Complete blood count for systemic infection concern

›Leukocytosis as supportive not diagnostic

›Normal count does not exclude invasive disease in immunocompromised

›C reactive protein for suspected malignant otitis externa

›Elevated values supporting inflammatory burden

›Trend utility for treatment response

›ESR for suspected skull base osteomyelitis

›Elevated values common in malignant otitis externa

›Trend utility during prolonged therapy

›Blood cultures if sepsis physiology

›Yield highest when febrile or unstable

Microbiology

›Culture strategy

›Canal swab culture for recurrent or refractory disease

›Prior topical antibiotic failure

›Immunocompromised host

›Suspicion for fungal infection

›Culture limitations

›Contamination from colonizing flora

›Clinical response remains primary endpoint in uncomplicated disease

06Diagnostic Tests/dt51

Scoring Systems

›Risk stratification framework

›Uncomplicated acute otitis externa category

›Localized canal inflammation

›No fever

›No periauricular cellulitis

›No cranial neuropathy

›No immunocompromised host

›Severe acute otitis externa category

›Marked canal edema with near occlusion

›Severe otalgia limiting sleep or function

›Failure of topical therapy at 48 to 72 hours

›Periauricular cellulitis

›Suspected malignant otitis externa category

›Diabetes or immunocompromised host

›Severe nocturnal otalgia

›Granulation tissue in canal

›Cranial nerve deficits

›Elevated ESR or CRP if obtained

MRI

›Skull base and soft tissue extension

›Indications

›Suspected malignant otitis externa with cranial neuropathy

›Concern for skull base osteomyelitis extent

›Concern for intracranial extension

›Advantages

›Soft tissue delineation

›Marrow involvement sensitivity

›Limitations

›Availability and time

›Motion artifact in severe pain

›Less detailed bony cortex evaluation than CT

›Temporal bone assessment

›Indications

›Suspected malignant otitis externa

›Suspected mastoiditis

›Suspected deep extension or abscess

›Technique considerations

›CT temporal bone with contrast when abscess or soft tissue extension concern

›Noncontrast CT temporal bone for bony erosion screening

›Interpretation pearls

›Bony erosion of external auditory canal suggesting invasive disease

›Mastoid opacification with clinical mastoiditis correlation

›Evidence note

›ACEP Level C recommendation for imaging when invasive complications suspected

Ultrasound

›Point of care applications

›Periauricular soft tissue ultrasound for cellulitis versus abscess

›Fluid collection supporting drainage need

›Cobblestoning supporting cellulitis

›Lymph node ultrasound for reactive adenopathy context

›Limitations

›Poor visualization of bony structures

›Not a rule out test for malignant otitis externa or mastoiditis

07Disposition/dispo18

Outpatient management

›Discharge suitability

›Uncomplicated acute otitis externa category features

›Pain controlled with oral regimen

›Reliable drop administration plan

›Follow up access within 3 to 7 days if not improving

›Follow up targets

›Primary care follow up for routine cases

›ENT follow up for recurrent disease

›Recheck in 48 to 72 hours if severe canal edema or wick placement

Admission and transfer

›Admission indications

›Suspected malignant otitis externa

›Cranial neuropathy

›Sepsis physiology

›Immunocompromised with severe disease

›Failure of outpatient therapy with worsening extension

›Transfer and higher level care triggers

›Need for urgent ENT procedural care not available locally

›Suspected skull base osteomyelitis requiring prolonged IV therapy

08Treatment/t122

Analgesia and symptom control

›Pain control plan

›Acetaminophen oral

›Adult dosing

›650 mg every 6 hours as needed

›Maximum 3000 mg per 24 hours when no risk factors

›Pediatrics dosing

›15 mg per kg every 6 hours as needed

›Maximum 60 mg per kg per 24 hours

›Ibuprofen oral

›Adult dosing

›400 mg every 6 to 8 hours as needed

›Maximum 2400 mg per 24 hours

›Pediatrics dosing

›10 mg per kg every 6 to 8 hours as needed

›Maximum 40 mg per kg per 24 hours

›If severe pain despite above, short course opioid strategy

›Hydromorphone oral

›1 mg every 6 hours as needed

›Avoid in opioid naive when possible

›Oxycodone oral

›5 mg every 6 hours as needed

›Avoid with significant respiratory risk

›Antiemetic support

›Ondansetron oral disintegrating tablet

›4 mg every 8 hours as needed

Canal management and drop delivery

›Aural toilet principles

›Debris removal to improve drop penetration

›Irrigation avoidance when tympanic membrane integrity uncertain

›Suction under direct visualization when available

›Ear wick strategy

›Indications

›Marked canal edema limiting drop delivery

›Technique considerations

›Compressed wick placement under visualization

›Frequent drop saturation to expand wick

›Reassessment

›Wick removal or replacement at 24 to 72 hours based on swelling

Topical antimicrobial therapy

›First line topical regimens for uncomplicated disease

›Fluoroquinolone based drops preferred when tympanic membrane perforation possible

›Ofloxacin otic 0.3 percent

›Adult dosing

›10 drops once daily for 7 days

›Pediatrics dosing

›5 drops once daily for 7 days

›Safety

›Non ototoxic profile for perforation concern

›Ciprofloxacin with hydrocortisone otic

›Adult dosing

›3 drops twice daily for 7 days

›Pediatrics dosing

›3 drops twice daily for 7 days when age appropriate per product labeling

›Rationale

›Steroid component reducing pain and edema

›Aminoglycoside containing drops only when tympanic membrane clearly intact

›Neomycin polymyxin B hydrocortisone otic

›Adult dosing

›3 to 4 drops three to four times daily for 7 to 10 days

›Pediatrics dosing

›3 drops three to four times daily for 7 to 10 days

›Precautions

›Avoid if perforation possible due to ototoxicity risk

›Contact dermatitis risk

›Dosing technique education embedded in plan

›Warm drops in hand before instillation

›Position with affected ear up for 3 to 5 minutes after drops

›Gentle tragal pumping to distribute drops

When to add systemic antibiotics

›Systemic therapy indications

›Periauricular cellulitis extending beyond canal

›Fever with systemic symptoms

›Immunocompromised host

›Suspected malignant otitis externa

›Oral antibiotics for cellulitis with low malignant concern

›Cephalexin oral

›Adult dosing

›500 mg four times daily for 5 to 7 days

›Pediatrics dosing

›25 mg per kg per day divided every 6 to 8 hours for 5 to 7 days

›Coverage note

›Streptococci and MSSA coverage

›If MRSA risk factors, add or substitute MRSA active agent per local patterns

›Doxycycline oral

›Adult dosing

›100 mg twice daily for 5 to 7 days

›Pediatrics precaution

›Avoid in children under 8 years

›Malignant otitis externa therapy pathway

›Initial IV antipseudomonal therapy

›Piperacillin tazobactam IV

›4.5 g every 6 hours

›Renal adjustment required

›Cefepime IV

›2 g every 8 to 12 hours

›Renal adjustment required

›Oral step down when appropriate and organism susceptible

›Ciprofloxacin oral

›750 mg twice daily

›Prolonged duration under specialist guidance

›Monitoring and endpoints

›Pain trajectory as key marker

›ESR or CRP trend when obtained

›Imaging follow up coordinated by ENT or ID

›Evidence note

›ACEP Level C recommendation for urgent imaging and specialist management when suspected

Antifungal strategy

›Otomycosis management

›Canal debridement as cornerstone

›Topical acidifying agent option

›Acetic acid 2 percent otic

›4 to 6 drops four times daily for 7 days

›Avoid if tympanic membrane perforation possible

›Topical antifungal option

›Clotrimazole 1 percent solution

›Application frequency per local ENT protocol

›Avoid middle ear exposure when perforation possible

›Reassessment needs

›High recurrence without debris removal

Treatment evidence summary

›Guideline aligned statements

›Topical antibiotic with or without steroid improves pain and clinical cure in uncomplicated disease

›Class I recommendation based on specialty guideline consensus

›Ear wick improves delivery when canal edema obstructs drops

›ACEP Level C recommendation

›Systemic antibiotics reserved for extension or high risk hosts

›Class I recommendation based on specialty guideline consensus

09Special Populations/sp27

Pregnancy

›Pregnancy considerations

›Topical therapy preference

›Fluoroquinolone otic drops as low systemic absorption option

›Avoid systemic antibiotics unless clear extension

›Analgesia selection

›Acetaminophen as first line

›NSAID avoidance in later pregnancy per obstetric guidance

›Escalation triggers

›Fever or cellulitis extension prompting obstetric aware management

Geriatric

›Older adult considerations

›Diabetes prevalence and malignant otitis externa risk

›Lower threshold for imaging and ENT involvement

›Medication safety

›NSAID renal and GI risk

›Opioid fall risk

›Hearing aids

›Temporary discontinuation during acute treatment when feasible

Pediatrics

›Pediatric considerations

›Weight based dosing for analgesics

›Drop administration barriers

›Caregiver instruction emphasis

›Recheck at 48 to 72 hours for severe edema or wick

›Systemic antibiotic selection

›Cellulitis extension pathway aligned to pediatric skin infection guidance

›Prevention counseling

›Avoid cotton swabs

›Dry ear after swimming

10Background/b29

Epidemiology

›Epidemiology overview

›Common outpatient and ED diagnosis in warm and humid seasons

›Swimmer associated risk pattern

›Higher recurrence with underlying dermatitis or frequent water exposure

Pathophysiology

›Mechanistic framework

›Canal skin barrier disruption

›Moisture maceration

›Microtrauma

›pH alteration

›Local inflammation cycle

›Edema causing obstruction

›Debris retention promoting bacterial growth

›Malignant otitis externa pathway

›Invasive infection spreading to cartilage and bone

›Skull base osteomyelitis risk in diabetes and immunocompromise

Therapeutic Considerations

›Why topical therapy works

›High local antibiotic concentration

›Limited systemic adverse effects

›Steroid component reducing edema and pain

›Reasons for treatment failure

›Inadequate drop delivery due to occlusion

›Nonadherence due to pain or technique

›Incorrect diagnosis

›Fungal infection

›Resistant organism in recurrent cases

›Prevention principles

›Moisture reduction

›Trauma avoidance

›Dermatitis control

11Patient Discharge Instructions/pdi34

Copy discharge instructions

›Discharge instructions

›Diagnosis explanation

›Ear canal skin infection or inflammation

›Expected improvement within 48 to 72 hours after correct drop use

›Medication use

›Ear drops exactly as prescribed

›Technique

›Lay with affected ear up after drops for 3 to 5 minutes

›Gentle tragal pumping after drops

›Activity and water precautions

›Keep ear dry during treatment

›No swimming until symptoms resolved

›Shower precautions with cotton ball lightly coated in petroleum jelly at entrance of ear

›No cotton swabs or objects in ear canal

›Pain control

›Acetaminophen or ibuprofen as directed unless contraindicated

›Follow up plan

›Recheck in 48 to 72 hours if severe pain or swelling

›Routine follow up in 3 to 7 days if not clearly improving

›Return to ED now

›Fever or chills

›Worsening pain after 48 to 72 hours of drops

›Spreading redness of ear or face

›New swelling behind ear

›Facial weakness

›Trouble swallowing or speaking

›Severe headache or neck stiffness

›Uncontrolled diabetes symptoms or high sugars with illness

›Coding and diagnosis labels

›ICD-10 acute otitis externa unspecified H60.3

›ICD-10 acute swimmer ear right H60.31

›ICD-10 acute swimmer ear left H60.32

›ICD-10 acute swimmer ear bilateral H60.33

›SNOMED CT concept acute otitis externa disorder term for documentation

12References/r12

Clinical guidelines and evidence sources

›Reference set

›American Academy of Otolaryngology Head and Neck Surgery Foundation guideline on acute otitis externa

›Infectious Diseases references on malignant otitis externa and skull base osteomyelitis

›Emergency medicine reference texts for ED management pathways

›Antimicrobial stewardship guidance on topical versus systemic therapy for otitis externa

Evidence grading conventions used

›Evidence and recommendation labels

›ACEP Level A high certainty evidence

›ACEP Level B moderate certainty evidence

›ACEP Level C consensus or limited evidence

›Class I recommended or indicated

›Class IIa reasonable

›Class IIb may be considered

Learn More: Otitis externa→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.